NASDAQ · Biotechnology

Allogene Therapeutics Inc (ALLO)

$1.46 +4.29%

Add alert

30 Oversold Daily RSI (14) · 9 Oct 2026

Moving averages

SMA 200$1.98-26.26%

Company profile

Allogene Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and markets genetically engineered allogeneic T-cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.

SectorHealthcare

IndustryBiotechnology

Market cap$614.97M

P/E ratioNone

EPS$-0.66

Beta0.476

Dividend yield0.00%

52-week high$4.46

52-week low$1.04

Similar stocks in Biotechnology

BNTX BioNTech SE RSI 48 VRTX Vertex Pharmaceuticals Inc RSI 46 CRSP CRISPR Therapeutics AG RSI 47 IOVA Iovance Biotherapeutics Inc RSI 73 MRNA Moderna Inc RSI 72 VKTX Viking Therapeutics Inc RSI 40 SRPT Sarepta Therapeutics Inc RSI 43 EDIT Editas Medicine Inc RSI 56 IBRX ImmunityBio Inc RSI 67 NVAX Novavax Inc RSI 68

Free forever

RSI alerts for ALLO

Get an email the moment Allogene Therapeutics Inc crosses into oversold or overbought territory. Nothing else, ever.

Add alert

Data last updated 13 September 2026 at 1:28 PM EDT